

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

<sup>Pr</sup> **RIVA LEUCOVORIN**

Leucovorin Calcium Tablets

Tablets, 5 mg leucovorin (as leucovorin calcium), Oral

USP

Folic Acid Derivative

**Laboratoire Riva Inc.**

660 Boul. Industriel

Blainville, Quebec

J7C 3V4

[www.labriva.com](http://www.labriva.com)

Date of Initial Authorization:

NOV 15, 2019

Date of Revision:

APR 28, 2023

Submission Control Number: 270579

## RECENT MAJOR LABEL CHANGES

<a href="#">3 SERIOUS WARNINGS AND PRECAUTIONS BOX</a>	04/2023
<a href="#">4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment</a>	04/2023
<a href="#">7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women</a>	04/2023
<a href="#">7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics</a>	04/2023

## TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

<b>RECENT MAJOR LABEL CHANGES</b> .....	<b>2</b>
<b>TABLE OF CONTENTS</b> .....	<b>2</b>
<b>PART I: HEALTH PROFESSIONAL INFORMATION</b> .....	<b>4</b>
<b>1 INDICATIONS</b> .....	<b>4</b>
1.1 Pediatrics .....	4
1.2 Geriatrics .....	4
<b>2 CONTRAINDICATIONS</b> .....	<b>4</b>
<b>3 SERIOUS WARNINGS AND PRECAUTIONS BOX</b> .....	<b>4</b>
<b>4 DOSAGE AND ADMINISTRATION</b> .....	<b>5</b>
4.2 Recommended Dose and Dosage Adjustment .....	5
4.4 Administration .....	6
<b>5 OVERDOSAGE</b> .....	<b>6</b>
<b>6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING</b> .....	<b>7</b>
<b>7 WARNINGS AND PRECAUTIONS</b> .....	<b>7</b>
7.1 Special Populations .....	9
7.1.1 Pregnant Women .....	9
7.1.2 Breast-feeding .....	9
7.1.3 Pediatrics .....	9
7.1.4 Geriatrics .....	9
<b>8 ADVERSE REACTIONS</b> .....	<b>10</b>
8.1 Adverse Reaction Overview .....	10
8.2 Clinical Trial Adverse Reactions .....	10

8.5	Post-Market Adverse Reactions .....	11
<b>9</b>	<b>DRUG INTERACTIONS .....</b>	<b>11</b>
9.1	Serious Drug Interactions .....	11
9.2	Drug Interactions Overview .....	12
9.3	Drug-Behavioural Interactions.....	12
9.4	Drug-Drug Interactions .....	13
9.5	Drug-Food Interactions.....	13
9.6	Drug-Herb Interactions.....	13
9.7	Drug-Laboratory Test Interactions.....	13
<b>10</b>	<b>CLINICAL PHARMACOLOGY .....</b>	<b>14</b>
10.1	Mechanism of Action.....	14
10.2	Pharmacodynamics .....	14
10.3	Pharmacokinetics .....	14
<b>11</b>	<b>STORAGE, STABILITY AND DISPOSAL .....</b>	<b>15</b>
<b>12</b>	<b>SPECIAL HANDLING INSTRUCTIONS.....</b>	<b>15</b>
<b>PART II: SCIENTIFIC INFORMATION .....</b>		<b>16</b>
<b>13</b>	<b>PHARMACEUTICAL INFORMATION.....</b>	<b>16</b>
<b>14</b>	<b>CLINICAL TRIALS .....</b>	<b>17</b>
14.2	Comparative Bioavailability Studies.....	17
<b>15</b>	<b>MICROBIOLOGY .....</b>	<b>18</b>
<b>16</b>	<b>NON-CLINICAL TOXICOLOGY .....</b>	<b>18</b>
<b>17</b>	<b>SUPPORTING PRODUCT MONOGRAPHS.....</b>	<b>18</b>
<b>PATIENT MEDICATION INFORMATION.....</b>		<b>19</b>

## PART I: HEALTH PROFESSIONAL INFORMATION

### 1 INDICATIONS

RIVA LEUCOVORIN (leucovorin calcium) is indicated for:

- diminishing the toxicity and counteracting the effect of impaired methotrexate elimination.
- treatment of megaloblastic anemias due to folate deficiency, as in sprue, nutritional deficiency, megaloblastic anemias of pregnancy and infancy.

#### 1.1 Pediatrics

Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see [7 WARNINGS AND PRECAUTIONS, 7.1.3 Pediatrics](#)).

#### 1.2 Geriatrics

Geriatrics: Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see [7 WARNINGS AND PRECAUTIONS, General](#) and [7.1.4 Geriatrics](#)).

### 2 CONTRAINDICATIONS

RIVA LEUCOVORIN therapy is contraindicated in patients with:

- Known hypersensitivity to the active substance or to any of the excipients. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).
- Pernicious anemia or other megaloblastic anemias where Vitamin B<sub>12</sub> is deficient. A hematologic remission may occur while neurologic manifestations continue to progress.

### 3 SERIOUS WARNINGS AND PRECAUTIONS BOX

#### Serious Warnings and Precautions

- RIVA LEUCOVORIN should only be used with 5-fluorouracil or methotrexate under the direct supervision of a clinician experienced in the use of cancer chemotherapeutic agents.
- Cases of Stevens - Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), some fatal, have been reported in patients receiving leucovorin calcium in combination with other agents known to be associated with these disorders.
- Fatalities have occurred as a result of gastrointestinal toxicity (particularly mucositis and diarrhea) associated with leucovorin calcium use.
- Fatalities have occurred as a result of myelosuppression associated with leucovorin calcium use.
- Anaphylactoid/anaphylactic reactions (including shock) have occurred in patients administered leucovorin calcium.

## 4 DOSAGE AND ADMINISTRATION

### 4.2 Recommended Dose and Dosage Adjustment

#### *Impaired methotrexate Elimination or Accidental Overdosage*

RIVA LEUCOVORIN rescue should begin as soon as possible after an inadvertent overdosage and within 24 hours of methotrexate administration when there is delayed excretion (see [7 WARNINGS AND PRECAUTIONS](#)). As the time interval between the administration of antifolate and RIVA LEUCOVORIN rescue increases, the effectiveness of RIVA LEUCOVORIN in counteracting toxicity decreases.

There are no fixed guidelines regarding the dose of methotrexate that triggers an automatic subsequent leucovorin calcium administration, since tolerance to this folate antagonist depends on various factors. The dose of methotrexate varies, nevertheless folinate rescue is necessary when methotrexate is given at doses exceeding 500 mg/m<sup>2</sup> and has to be considered with doses of 100 mg - 500 mg/m<sup>2</sup>.

Leucovorin calcium rescue treatment should commence approximately 24 hours after the beginning of methotrexate infusion. Dosage regimens vary depending upon the dose of methotrexate administered. In general, leucovorin calcium should be administered at a dose of 15 mg (approximately 10 mg/m<sup>2</sup>) every 6 hours for 10 doses, either parenterally by intramuscular injection, bolus intravenous injection, intravenous infusion, or orally using leucovorin calcium tablets.

Monitoring of the serum methotrexate (MTX) concentration is essential in determining the optimal dose and duration of therapy. If serum creatinine increases after methotrexate therapy or if methotrexate plasma concentrations are above certain threshold (see **Table 1**), the dose of leucovorin calcium should be increased according to the plasma methotrexate concentrations as soon as the risk is recognized. In the presence of gastrointestinal toxicity, nausea, or vomiting, leucovorin calcium should be administered parenterally. In the case of intravenous administration, no more than 160 mg of leucovorin calcium should be injected per minute due to the calcium content of the solution. Further, oral administration of doses greater than 25 mg is not recommended since the digestive absorption of leucovorin calcium is saturable; these doses should be administered parenterally.

In addition to leucovorin calcium administration, measures to ensure the prompt excretion of methotrexate are an integral part of the leucovorin calcium rescue treatment. These measures include:

- a) Maintenance of urine output above 2,500 mL/24 hr in adults by increased oral or intravenous fluids 12 hours before and for 36 hours after the end of methotrexate infusion.
- b) Alkalinisation of urine so that the urinary pH is greater than 7.0 before methotrexate infusion. Foods, drinks and drugs that may increase urinary acidity should be avoided during the therapy.
- c) Plasma methotrexate concentration and serum creatinine should be measured at least 24, 48, and 72 hours after the initiation of the methotrexate infusion. These measurements must be continued until the plasma methotrexate level is less than  $5 \times 10^{-8}$  molar (0.05 µm).

Delayed methotrexate excretion may be seen in some patients. This may be caused by a third space accumulation (as seen in ascites or pleural effusion for example), renal insufficiency or inadequate hydration (see [7 WARNINGS AND PRECAUTIONS](#)). Under such circumstances, higher doses of leucovorin calcium and/or prolonged administration may be indicated. Some dosage and administration guidelines are given in **Table 1**.

**Table 1 – Dosage and Administration Guidelines for Leucovorin Calcium Rescue**

Clinical situation	Laboratory findings	Leucovorin calcium dosage and duration
Normal methotrexate elimination	Serum methotrexate level $\leq 10 \mu\text{M}$ at 24 hours after administration, $\leq 1 \mu\text{M}$ at 48 hours, and $< 0.1 \mu\text{M}$ at 72 hours.	15 mg PO, IM, or IV every 6 hours for 60 hours (10 doses starting at 24 hours after start of methotrexate infusion).
Delayed late methotrexate elimination	Serum methotrexate level remaining $> 0.1 \mu\text{M}$ at 72 hours, and $> 0.1 \mu\text{M}$ at 96 hours after administration.	Continue 15 mg PO, IM, or IV every 6 hours, until methotrexate level is less than $0.1 \mu\text{M}$ .
Delayed early methotrexate elimination and/or evidence of acute renal failure	Serum methotrexate level of $>10 \mu\text{M}$ at 24 hours, or $> 1 \mu\text{M}$ at 48 hours after administration OR a 100% or greater increase in serum creatinine level at 24 hours after methotrexate administration.	150 mg IV every 3 hours, until methotrexate level is less than $1 \mu\text{M}$ ; then 15 mg IV every 3 hours until methotrexate level is less than $0.1 \mu\text{M}$ .

Hydration (3 L/d) and urinary alkalinization with  $\text{NaHCO}_3$  should be employed concomitantly. The bicarbonate dose should be adjusted to maintain the urine pH at 7.0 or greater.

*Megaloblastic Anemia Due to Folic Acid Deficiency*

Doses up to 15 mg daily have been suggested.

Health Canada has not authorized an indication for pediatric use.

**4.4 Administration**

Tablets are administered orally.

**5 OVERDOSAGE**

Folic acid is a water-soluble vitamin converted in the body by the action of folate reductase to folinic acid (leucovorin calcium), which is rapidly eliminated in the urine.

Folic acid has low acute and chronic toxicity in humans. **There have been no reported sequelae in patients who have received significantly more leucovorin calcium than the recommended dosage. However, excessive amounts of leucovorin calcium may nullify the chemotherapeutic effect of folic acid antagonists.** No adverse effects have been noted in adults after the ingestion of 400 mg/day for 5 months or 10 mg/day for 5 years.

**Should overdose of the combination of 5-fluorouracil and leucovorin calcium occur, the overdose instructions for 5-FU should be followed.**

For management of a suspected drug overdose, contact your regional poison control centre.

## 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 2 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Oral	Tablet, 5 mg Each tablet contains 5 mg of leucovorin as leucovorin calcium (also known as calcium folinate).	Colloidal Silicon Dioxide, Croscarmellose Sodium, Magnesium Stearate, Microcrystalline Cellulose and Monohydrate Lactose.

RIVA LEUCOVORIN 5 mg tablets are supplied as white to off white, round convex tablets, engraved “IT” above bisect and “54” below bisect on one side, other side is plain.

### Availability:

Bottles of 24 tablets

Bottles of 100 tablets

## 7 WARNINGS AND PRECAUTIONS

### General

Since leucovorin calcium may enhance the toxicity of fluorouracil, leucovorin calcium/fluorouracil combination therapy for advanced colorectal cancer should be administered under the supervision of a physician experienced in the use of antimetabolite cancer chemotherapy. Particular care should be taken in the treatment of elderly or debilitated colorectal cancer patients (see [9 DRUG INTERACTIONS](#) and [7.1.4 Geriatrics](#)).

Leucovorin calcium should only be used with 5-fluorouracil or methotrexate under the direct supervision of a clinician experienced in the use of cancer chemotherapeutic agents.

Treatment-related deaths have been sporadically reported in patients treated with RIVA LEUCOVORIN plus fluorouracil combination therapy regimens. In general, diarrhea or stomatitis/mucositis are the first indications that severe and potentially life-threatening toxicity could develop. Patients who experience these symptoms while receiving any combination therapy regimen incorporating RIVA LEUCOVORIN plus fluorouracil should be carefully followed and further therapy should be withheld until these symptoms resolve.

### Gastrointestinal

Gastrointestinal toxicities (particularly stomatitis and diarrhea) are observed more commonly and may be more severe in patients receiving leucovorin calcium plus fluorouracil combination (see [9 DRUG INTERACTIONS, 9.2 Drug Interactions Overview](#)).

Therapy with RIVA LEUCOVORIN/fluorouracil must not be initiated or continued in patients who have symptoms of gastrointestinal toxicity of any severity, until those symptoms have resolved. Patients with diarrhea must be monitored with particular care until the diarrhea has resolved, as rapid clinical

deterioration leading to death can occur. Elderly or debilitated patients are at greater risk for severe toxicity receiving this therapy.

### **Hematologic**

RIVA LEUCOVORIN (leucovorin calcium) treatment may mask pernicious anemia and other megaloblastic anemias resulting from vitamin B<sub>12</sub> deficiency.

RIVA LEUCOVORIN should not be used for the treatment of macrocytosis caused by direct or indirect DNA synthesis inhibitors (e.g. hydroxycarbamide, cytarabine, mercaptopurine, thioguanine).

### **Monitoring and Laboratory Tests**

The following provides general advice for monitoring patients; however, specific monitoring recommendations may vary with local medical practice.

#### **5-fluorouracil/leucovorin calcium therapy**

Complete blood count (CBC) with differential and platelets: prior to each treatment; weekly during the first two courses; at time of anticipated white blood cell (WBC) nadir in all courses thereafter.

Electrolytes and liver function tests: prior to each treatment for the first three courses and prior to every other course thereafter.

#### **Methotrexate/leucovorin calcium therapy**

Serum creatinine levels and serum methotrexate levels: at least once daily.

Urine pH: in cases of methotrexate overdose or delayed excretion, monitor as appropriate, to ensure maintenance of pH  $\geq 7.0$ .

### **Neurologic**

Seizures and/or syncope have been reported rarely in cancer patients receiving leucovorin calcium, usually in association with fluoropyrimidine and anti-epileptic drugs such as phenobarbital, phenytoin, primidone, and succinimides administration (see [9 DRUG INTERACTIONS](#)).

In epileptic patients treated with phenobarbital, phenytoin, primidone, and succinimides there is a risk to increase the frequency of seizures due to a decrease of plasma concentrations of anti-epileptic drugs. Clinical monitoring, possibly monitoring of the plasma concentrations and, if necessary, dose adaptation of the anti-epileptic drug during leucovorin calcium administration and after discontinuation is recommended.

### **Reproductive Health: Female and Male Potential**

- **Fertility**

Leucovorin calcium is an intermediate product in the metabolism of folic acid and occurs naturally in the body. No fertility studies have been conducted with leucovorin calcium in animals.

### **Skin**

Cases of Stevens - Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), some fatal, have been reported in patients receiving leucovorin calcium in combination with other agents known to be associated with these disorders. A contributory role of leucovorin in these occurrences of SJS/TEN cannot be excluded (see [3 SERIOUS WARNINGS AND PRECAUTIONS](#)).



## **7.1 Special Populations**

### **7.1.1 Pregnant Women**

There are no adequate and well-controlled clinical studies conducted in pregnant or breast-feeding women. Animal studies do not indicate reproductive toxicity (see [16 NON-CLINICAL TOXICOLOGY](#)). There are no indications that folic acid induces harmful effects if administered during pregnancy. During pregnancy, 5-fluorouracil and methotrexate should only be administered on strict indications, where the benefits of the drug to the mother should be weighed against possible hazards to the foetus. Should treatment with methotrexate or other folate antagonists take place despite pregnancy or lactation, there are no limitations as to the use of RIVA LEUCOVORIN (leucovorin calcium) to diminish toxicity or counteract the effects.

5-fluorouracil use is generally contraindicated during pregnancy and contraindicated during breast-feeding; this applies also to the combined use of RIVA LEUCOVORIN (leucovorin calcium) with 5-fluorouracil.

Please refer also to the health-care professional label for methotrexate, other folate antagonists and 5-fluorouracil-containing medicinal products.

### **7.1.2 Breast-feeding**

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when RIVA LEUCOVORIN is administered to a nursing mother.

### **7.1.3 Pediatrics**

Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

### **7.1.4 Geriatrics**

Geriatrics: Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see [7 WARNINGS AND PRECAUTIONS, General](#)). Deaths from severe enterocolitis, diarrhea and dehydration have been reported in elderly patients receiving leucovorin and fluorouracil. Concomitant granulocytopenia and fever were present in some but not all of the patients.

## 8 ADVERSE REACTIONS

### 8.1 Adverse Reaction Overview

Allergic sensitization, including anaphylactoid/anaphylactic reactions (including shock) and urticaria, has been reported following administration of leucovorin calcium.

**Table 3 –Adverse Reactions associated with Leucovorin Calcium**

System Organ Class	Adverse Reaction
<b><i>Immune system disorders</i></b>	
Frequency undetermined	Allergic reactions, urticarial
Very Rare	Anaphylactoid/ anaphylactoid reactions (including shock)
<b><i>Nervous System disorders</i></b>	
Rare	Seizures and/or syncope
<b><i>General disorders and administration site conditions</i></b>	
Frequency undetermined	Fever

### 8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

#### **Leucovorin calcium in Combination with 5-fluorouracil (5-FU)**

In combination regimens, the toxicity profile of 5-FU is enhanced by leucovorin calcium. The most common manifestations are mucositis, stomatitis, leukopenia and/or diarrhea, which may be dose-limiting. In clinical trials with this drug combination, these toxicities were found to be reversible with appropriate modification of 5-FU administration.

Generally, the safety profile depends on the applied regimen of 5-fluorouracil due to enhancement of the 5-fluorouracil induced toxicities. Additional undesirable effects when used in combination with 5-fluorouracil:

**Table 4 –Adverse Reactions associated with Leucovorin Calcium in Combination with 5-FU**

<b>System Organ Class</b>	<b>Adverse Reaction</b>
<b><i>Gastrointestinal disorders</i></b>	
Very common	Nausea and Vomiting, diarrhea
<b><i>Hepatobiliary disorders</i></b>	
Frequency undetermined	Hyperammonemia
<b><i>Skin and subcutaneous tissue disorders</i></b>	
Common	Palmar-Plantar Erythrodysesthesia
<b><i>General disorders and administration site conditions</i></b>	
Very common	Mucositis, including stomatitis and cheilitis

### 8.5 Post-Market Adverse Reactions

Cases of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), some fatal, have been reported in patients receiving leucovorin calcium in combination with other agents known to be associated with these disorders. A contributory role of leucovorin in these occurrences of SJS/TEN cannot be excluded.

Fatalities have occurred as a result of gastrointestinal toxicity (predominantly mucositis and diarrhea) and myelosuppression. In patients with diarrhea, rapid clinical deterioration leading to death can occur.

## 9 DRUG INTERACTIONS

### 9.1 Serious Drug Interactions

#### Serious Drug Interactions

- Treatment-related deaths have been sporadically reported in patients treated with leucovorin calcium plus fluorouracil combination therapy regimens. In general, diarrhea or stomatitis/mucositis are the first indications that severe and potentially life-threatening toxicity could develop. Patients who experience these symptoms while receiving any combination therapy regimen incorporating RIVA LEUCOVORIN plus fluorouracil should be carefully followed and further therapy should be withheld until these symptoms resolve (see [9.4 Drug-Drug Interactions](#)).

## 9.2 Drug Interactions Overview

Leucovorin calcium may diminish the effect of anti-epileptic substances: phenobarbital, primidone, phenytoin and succinimides, and may increase the frequency of seizures (a decrease of plasma levels of enzymatic inductor anticonvulsant drugs may be observed because the hepatic metabolism is increased as folates are one of the cofactors). Seizures and/or syncope have been reported rarely in cancer patients receiving leucovorin, usually in association with fluoropyrimidine administration, and most commonly in those with CNS metastases or other predisposing factors; however, a causal relationship has not been established.

In epileptic patients treated with phenobarbital, phenytoin, primidone, and succinimides there is a risk to increase the frequency of seizures due to a decrease of plasma concentrations of anti-epileptic drugs. Clinical monitoring, possibly monitoring of the plasma concentrations and, if necessary, dose adaptation of the anti-epileptic drug during RIVA LEUCOVORIN administration and after discontinuation is recommended.

When leucovorin calcium is given in conjunction with a folic acid antagonist (eg, cotrimoxazole, pyrimethamine, methotrexate, antibiotic with antifolic effect) the efficacy of the folic acid antagonist may either be reduced or completely neutralised.

Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin calcium enter the CSF primarily as 5-methyltetrahydrofolate and, in humans, remain 1-3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration. However, high doses of leucovorin calcium may reduce the efficacy of intrathecally administered methotrexate.

Leucovorin calcium may enhance the toxicity of fluorouracil (see [7 WARNINGS AND PRECAUTIONS](#)). When these drugs are administered concurrently in the palliative therapy of advanced colorectal cancer, the dosage of fluorouracil must be reduced. Although the toxicities observed in patients treated with the combination of leucovorin calcium plus fluorouracil are qualitatively similar to those observed in patients treated with fluorouracil alone, gastrointestinal toxicities (particularly stomatitis and diarrhea) are observed more commonly and may be more severe in patients receiving the combination (see [7 WARNINGS AND PRECAUTIONS](#)).

## 9.3 Drug-Behavioural Interactions

Interactions with behaviour have not been established.

## 9.4 Drug-Drug Interactions

**Table 5 - Established or Potential Drug-Drug Interactions**

Leucovorin	Source of Evidence	Effect	Clinical comment
Anticonvulsants (phenobarbital, primidone, phenytoin and succinimides)	T	Diminished effect	May increase the frequency of seizures
Folic acid antagonist (eg: cotrimoxazole, pyrimethamine, methotrexate, antibiotic with antifolic effect)	T	Diminished effect	Efficacy may be reduced or completely neutralized
Methotrexate	CT	Diminished effect	small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydrofolate and remain 1-3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration. High doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate
Fluorouracil	CT	Increased toxicity	toxicities were found to be reversible with appropriate modification of 5FU administration

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical

## 9.5 Drug-Food Interactions

Interactions with food have not been established.

## 9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

## 9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

## 10 CLINICAL PHARMACOLOGY

### 10.1 Mechanism of Action

Leucovorin calcium, the calcium salt of folinic acid (citrovorum factor), is a mixture of the diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid. The biologically active component of the mixture is the (-)-L-isomer. It is a metabolite of folic acid and an essential coenzyme for nucleic acid synthesis used in cytotoxic therapy.

### 10.2 Pharmacodynamics

Leucovorin calcium is a reduced form of folic acid, which is readily converted to other reduced folic acid derivatives (e.g., tetrahydrofolate).

Because it does not require reduction by dihydrofolate reductase as does folic acid, leucovorin calcium is not affected by blockage of this enzyme by folic acid antagonists (dihydrofolate reductase inhibitors). This allows purine and thymidine synthesis, and thus DNA, RNA and protein synthesis, to occur. Leucovorin calcium may limit methotrexate action on normal cells by competing with methotrexate for the same transport processes into the cell. Leucovorin calcium rescues bone marrow and gastrointestinal cells from methotrexate but has no apparent effect on pre-existing methotrexate nephrotoxicity.

Leucovorin calcium is extensively converted to 5-methyltetrahydrofolate in the intestine prior to absorption. In this form, it is a major component of the total active human serum folate. Oral absorption is saturable at doses above 25 mg.

Leucovorin calcium enhances the cytotoxicity of fluoropyrimidines such as 5-fluorouracil (5FU) by their metabolites, methylene tetrahydrofolate and fluorodeoxyuridine monophosphate, forming a stable ternary complex with thymidylate synthase and thereby decreasing intracellular levels of that enzyme and the product thymidylate. The cell then dies as a result of thymine starvation.

### 10.3 Pharmacokinetics

The pharmacokinetics after intravenous, intramuscular and oral administration of a 25 mg dose of leucovorin calcium were studied in male volunteers.

After intravenous administration, serum total reduced folates (as measured by *Lactobacillus casei* assay) reached a mean peak of 1259 ng/mL (range 897-1625). The mean time to peak was 10 minutes. This initial rise in total reduced folates was primarily due to the parent compound 5-formyl-THF (measured by *Streptococcus faecalis* assay), which rose to 1206 ng/mL at 10 minutes. A sharp drop in parent compound followed and coincided with the appearance of the metabolite (also active), 5-methyl-THF, which became the predominant circulating form of the drug. The mean peak of 5-methyl-THF was 258 ng/mL and occurred at 1.3 hours. The terminal half-life for total reduced folates was 6.2 hours.

After intramuscular injection, the mean peak of serum total reduced folates was 436 ng/mL (range 240-725) and occurred at 52 minutes. Similar to IV administration, the initial sharp rise was due to the parent compound. The mean peak of 5-formyl-THF was 360 ng/mL and occurred at 28 minutes. The level of the metabolite 5-methyl-THF increased subsequently over time until at 1.5 hours it represented 50% of the circulating total folates. The mean peak of 5-methyl-THF was 226 ng/mL at 2.8 hours. The terminal half-life of total reduced folates was 6.2 hours. There was no difference of statistical

significance between IM and IV administration in the AUC for total reduced folates, 5-formyl-THF or 5-methyl-THF.

After oral administration of leucovorin calcium reconstituted with the aromatic elixir, the mean peak concentration of serum total reduced folates was 393 ng/mL (range 160-550). The mean time to peak was 2.3 hours and the terminal half-life was 5.7 hours. The major component was the metabolite 5-methyltetrahydrofolate to which leucovorin calcium is partially converted in the intestinal mucosa. The mean peak of 5-methyl-THF was 367 ng/mL at 2.4 hours. The peak level of the parent compound was 51 ng/mL at 1.2 hours. The AUC of total reduced folates after oral administration of the 25 mg dose was 92% of the AUC after intravenous administration.

Following oral administration, leucovorin calcium is rapidly absorbed and enters the general body pool of reduced folates. Folate is concentrated in the liver and cerebrospinal fluid although distribution occurs to all body tissues. Folates are mainly excreted in the urine, with small amounts in the faeces. Parenteral administration of leucovorin calcium gives higher peak plasma levels than oral administration, but the total plasma folate pool of folinic acid plus its metabolite (N<sup>5</sup>methyl-H<sub>4</sub>-folate) remains unchanged. Oral absorption of leucovorin calcium is saturable at doses above 25 mg. The apparent bioavailability of leucovorin calcium was 97% for 25 mg, 75% for 50 mg and 37% for 100 mg.

Leucovorin calcium is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme of nucleic acid synthesis in cytotoxic chemotherapy. Leucovorin calcium is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Leucovorin calcium and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effect of folate antagonists by repletion of the reduced folate pool. Leucovorin calcium serves as a pre-reduced source of H<sub>4</sub> folate: it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid. Leucovorin calcium is also frequently used in the biochemical modulation of fluoropyridine (5-FU) to enhance its cytotoxic activity. 5-FU inhibits thymidylate synthase (TS), a key enzyme involved in pyrimidine biosynthesis, and leucovorin calcium enhances TS inhibition by increasing the intracellular folate pool, thus stabilizing the 5-FU-TS complex and increasing 5-FU activity. A folic acid deficiency is produced during therapy with the folic acid antagonists, aminopterin and amethopterin (methotrexate), used as antineoplastic agents and with the chemotherapeutic agent, pyrimethamine. These agents competitively inhibit the conversion of folic acid to folinic acid. Their affinity for folate reductase is so much greater than that of folic acid that not even large doses of folic acid will correct the drug-induced deficiency. In the event of a severe toxic reaction, the already reduced form, folinic acid, can be given, since it can be used directly to form new coenzyme.

## **11 STORAGE, STABILITY AND DISPOSAL**

### **RIVA LEUCOVORIN Tablets 5 mg:**

Tablets should be stored at 15-30°C. Protect from light. Keep out of reach and sight of children.

## **12 SPECIAL HANDLING INSTRUCTIONS**

There are no special handling instructions for this drug product.

## PART II: SCIENTIFIC INFORMATION

### 13 PHARMACEUTICAL INFORMATION


#### Drug Substance

Proper name: Leucovorin Calcium (USP) also known as Leucovorin calcium hydrate in Ph. Eur.

Chemical name: Calcium (2S)-2-[4-[[[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl]amino]benzamido]pentanedioate hydrate.

Molecular formula and molecular mass:  $C_{20}H_{21}CaN_7O_7 \times H_2O$ , 511.5 g/mol (calculated on the anhydrous basis)

Structural formula:



Physicochemical properties: Leucovorin Calcium occurs as a white to light yellow, crystalline powder. There is 0.004 mEq of calcium per mg of leucovorin in each tablet.

Solubility: Leucovorin Calcium is very soluble in water and practically insoluble in ethanol and acetone.

pH: 6.8-8.0

pKa: 3.1 – 4.8 – 10.4

Melting Point: The substance does not have a melting point. It decomposes above 250°C.

Hygroscopicity: The substance is hygroscopic.



## 14 CLINICAL TRIALS

The clinical trial data on which the original indication was authorized is not available.

### 14.2 Comparative Bioavailability Studies

A randomized, blinded, two-treatment, two-period, two-sequence, single-dose, crossover comparative bioavailability study of <sup>Pr</sup>RIVA LEUCOVORIN 5 mg tablets (Laboratoire Riva Inc.) with <sup>Pr</sup>LEDERLE LEUCOVORIN® 5 mg tablets (Pfizer Canada Inc.) was conducted in healthy, adult, male subjects under fasting conditions. Comparative bioavailability data from 26 subjects that were included in the statistical analysis are presented in the following table:

**SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA**

<b>Leucovorin (1 x 5 mg) Geometric Mean Arithmetic Mean (CV%)</b>				
<b>Parameter</b>	<b>Test<sup>1</sup></b>	<b>Reference<sup>2</sup></b>	<b>% Ratio of Geometric Means</b>	<b>90% Confidence Interval</b>
AUC <sub>T</sub> (ng·h/mL)	2823.94 2893.11 (20.88)	2751.20 2850.56 (26.23)	102.6	98.0 – 107.5
AUC <sub>I</sub> (ng·h/mL)	3105.81 3178.88 (21.19)	3023.53 3134.30 (27.06)	102.7	98.0 – 107.6
C <sub>max</sub> (ng/mL)	257.20 262.41 (18.64)	247.63 255.32 (24.12)	103.9	98.8 – 109.2
T <sub>max</sub> <sup>3</sup> (h)	1.50 (1.00 – 2.67)	1.50 (1.25 – 2.67)		
T <sub>½</sub> <sup>4</sup> (h)	10.42 (14.03)	10.34 (14.03)		

<sup>1</sup> <sup>Pr</sup>RIVA LEUCOVORIN (leucovorin as leucovorin calcium) tablets, 5 mg (Laboratoire Riva Inc.)

<sup>2</sup> <sup>Pr</sup>LEDERLE LEUCOVORIN® (leucovorin as leucovorin calcium) tablets, 5 mg (Pfizer Canada Inc.)

<sup>3</sup> Expressed as the median (range) only

<sup>4</sup> Expressed as the arithmetic mean (CV%) only

## **15 MICROBIOLOGY**

No microbiological information is required for this drug product.

## **16 NON-CLINICAL TOXICOLOGY**

Genotoxicity, carcinogenicity, and fertility studies have not been conducted with leucovorin calcium.

Embryo-fetal reproduction toxicity studies have been performed in rats and rabbits. Rats were dosed up to 1800 mg/m<sup>2</sup> which is 9 times the maximum recommended human dose, and rabbits were dosed up to 3300 mg/m<sup>2</sup> which is 16 times the maximum recommended human dose. There was no embryo-fetal toxicity noted in rabbits. At the maximum dose in rats, there was a slight increase in early embryonic resorptions and no other adverse effects on embryo-fetal development. No resorptions were noted in dose groups at 5 times the maximum recommended human dose.

## **17 SUPPORTING PRODUCT MONOGRAPHS**

1. LEDERLE LEUCOVORIN (Tablets, 5 mg), submission control 263375, Product Monograph, Pfizer Canada ULC. (OCT 04, 2022)

## PATIENT MEDICATION INFORMATION

### READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

#### Pr RIVA LEUCOVORIN

#### Leucovorin Calcium Tablets

Read this carefully before you start taking **RIVA LEUCOVORIN** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **RIVA LEUCOVORIN**.

#### Serious Warnings and Precautions

- RIVA LEUCOVORIN should only be used with 5-fluorouracil or methotrexate under the direct supervision of a healthcare professional experienced in the use of anti-cancer medicines.
- RIVA LEUCOVORIN can cause serious side effects. In some cases these side effects have been fatal:
  - **Severe skin reactions:** These include Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) and are more likely to occur if you are taking other medicines that are also known to cause these reactions.
  - **Gastrointestinal toxicity:** Inflammation and ulceration of the mucous membranes lining the digestive tract.
  - **Bone marrow suppression:** Large decrease in the production of blood cells and platelets by the bone marrow.
  - **Serious allergic reactions**

For more information on these and other serious side effects, see the **Serious side effects and what to do about them** table, below.

#### What is RIVA LEUCOVORIN used for?

RIVA LEUCOVORIN is used to:

- reduce the toxic effect of the medicine methotrexate if your body does not process methotrexate well.
- treat certain anemias (when your body does not have enough functional red blood cells) due to folate deficiency, such as in sprue, nutritional deficiency, and certain types of anemia that can happen during pregnancy and infancy.

#### How does RIVA LEUCOVORIN work?

RIVA LEUCOVORIN is a form of the vitamin folic acid. It reduces the toxic effects of methotrexate by competing with methotrexate to get into normal cells. This means RIVA LEUCOVORIN enters normal cells and not methotrexate which keeps them healthy.

### **What are the ingredients in RIVA LEUCOVORIN?**

Medicinal ingredient: Leucovorin calcium (also known as calcium folinate).

Non-medicinal ingredients: Colloidal Silicon Dioxide, Croscarmellose Sodium, Magnesium Stearate, Microcrystalline Cellulose and Monohydrate Lactose.

### **RIVA LEUCOVORIN comes in the following dosage forms:**

Tablet: 5 mg Leucovorin (as leucovorin calcium)

### **Do not use RIVA LEUCOVORIN if:**

- you are allergic (hypersensitive) to leucovorin calcium or any of the other ingredients of RIVA LEUCOVORIN (See **What are the ingredients in RIVA LEUCOVORIN?**)
- you have megaloblastic anaemia (a type of anemia where the bone marrow makes large, abnormal red blood cells) due to Vitamin B<sub>12</sub> deficiency

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take RIVA LEUCOVORIN. Talk about any health conditions or problems you may have, including if you:**

- have symptoms of stomach or intestinal disorders
- are taking any of the following:
  - anti-cancer medicines, such as hydroxycarbamide cytarabine, mercaptopurine, thioguanine
  - medicines to treat epilepsy, such as phenobarbital, primidone, phenytoin and succinimides
  - any medicine known to cause serious skin reactions like Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN)
- are pregnant or breastfeeding
- are lactose intolerant or have one of the following rare hereditary diseases:
  - Galactose intolerance
  - Lapp lactase deficiency
  - Glucose-galactose malabsorption
- Because lactose is a non-medicinal ingredient in **RIVA LEUCOVORIN**.

### **Other warnings you should know about**

**Blood tests and monitoring:** RIVA LEUCOVORIN can cause abnormal blood test results. Your healthcare professional will do blood tests regularly while you are being treated with RIVA LEUCOVORIN. They will check the health of your red and white blood cells and platelets as well as the health of your kidneys and liver. They will decide when to perform blood tests and will interpret the results.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

### Serious Drug Interactions

If you are taking RIVA LEUCOVORIN together with the anti-cancer medicine 5-fluorouracil (5FU) and you experience mouth inflammation, sores or ulcers, stomach or intestinal pain or diarrhea talk to your healthcare professional immediately. These could be signs of a serious, potentially life-threatening, interaction call **gastrointestinal toxicity**. See the **Serious side effects and what to do about them** table, below.

### The following may interact with RIVA LEUCOVORIN:

- anti-cancer medicines, such as 5-fluorouracil (5FU), methotrexate
- folic acid antagonists, such as cotrimoxazole (used to treat bacterial infections), pyrimethamine (used to treat parasitic infections), and other antibiotics that have an effect on folic acid
- medicines used to treat epilepsy, such as phenobarbital, primidone, phenytoin, succinimides

### How to take RIVA LEUCOVORIN:

- Take RIVA LEUCOVORIN exactly as your healthcare professional tells you to.

### Usual dose:

Your healthcare professional will decide on the dose that is right for you based on your weight, other medicines you are taking and the condition that is being treated.

### Overdose:

If you think you, or a person you are caring for, have taken too much RIVA LEUCOVORIN, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

### What are possible side effects from using RIVA LEUCOVORIN?

These are not all the possible side effects you may have when taking RIVA LEUCOVORIN. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

- nausea, vomiting
- red, swollen lips
- dizziness
- fever

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<b>VERY COMMON</b>			
<b>Gastrointestinal toxicity (inflammation and ulceration of the mucous membranes lining the digestive tract):</b> painful, red, shiny or swollen gums, tongue, mouth or throat sores or ulcers, blood in the mouth, difficult or painful swallowing or talking, dry mouth, mild burning, or pain when eating food, diarrhea			✓
<b>COMMON</b>			
<b>Palmar-plantar erythrodysesthesia (hand and foot syndrome):</b> red or swollen palms, thick calluses and blisters of the hands and soles of the feet, tingling or burning, tightness of the skin		✓	
<b>RARE</b>			
<b>Seizures (fit):</b> uncontrollable shaking with or without loss of consciousness			✓
<b>Syncope (fainting):</b> a temporary loss of consciousness due to a sudden drop in blood pressure		✓	
<b>UNKNOWN FREQUENCY</b>			
<b>Allergic reactions:</b> difficulty swallowing or breathing, wheezing, drop in blood pressure, feeling sick to your stomach and throwing up, hives or rash, swelling of the face, lips, tongue or throat, low blood pressure, confusion, reduced alertness, cold, moist skin, fast breathing, fast heartbeat			✓
<b>Bone marrow suppression (large decrease in the production of blood cells and platelets by the bone marrow):</b> bleeding, bruising, chills, fatigue, fever, infections, weakness, shortness of breath or other signs of infection			✓

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<b>Hyperammonemia (high ammonia levels in the blood):</b> confusion, irritability, refusal to eat meat or high protein products		✓	
<b>Severe skin reactions [Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)]:</b> redness, blistering and/or peeling of the skin and/or inside the lips, mouth, eyes, nasal passages or genitals, accompanied by fever, chills, tiredness, headache and cough, body aches or swollen glands, raised red or purple skin patches, possibly with blister or crust in the center, swollen lips, mild itching or burning			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

### Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

### Storage:

Store at 15°C - 30°C. Protect from light.

Keep out of reach and sight of children.

**If you want more information about RIVA LEUCOVORIN:**

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website ([www.labriva.com](http://www.labriva.com)), or by calling 1-800-363-7988.

This leaflet was prepared by:

**Laboratoire Riva Inc.**

660 Boul. Industriel  
Blainville, Quebec  
J7C 3V4  
[www.labriva.com](http://www.labriva.com)

Last Revised: April 28, 2023